High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma-Reference-Cited by-同舟云学术

High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma

Published:2023-10 Issue:10 Volume:4 Page:101214
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Cheng Yan,Sun Fumou,Alapat Daisy V.,Wanchai Visanu,Mery David,Guo Wancheng,Cao Huojun,Zhu Yuqi,Ashby Cody,Bauer Michael Anton,Nookaew Intawat,Siegel Eric R.,Ying Jun,Chen Jin-Ran,Gai Dongzheng,Peng Bailu,Xu Hongwei,Bailey Clyde,Al Hadidi Samer,Schinke Carolina,Thanendrarajan Sharmilan,Zangari Maurizio,Chesi Marta,Bergsagel P. Leif,van Rhee Frits,Janz Siegfried,Tricot Guido,Shaughnessy John D.,Zhan Fenghuang^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference58 articles.

1. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management;Rajkumar;Am. J. Hematol.,2022

2. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect;Alyea;Blood,2001

3. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation;Lokhorst;Blood,1997

4. Graft-versus-myeloma effect: proof of principle;Tricot;Blood,1996

5. Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort;Ri;Cancer Sci.,2022

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Momordin Ic that selectively reduces PD-L1 expression in multiple myeloma cells by recruiting SYVN1;Food Bioscience;2024-10

2. INHBA promotes tumor growth and induces resistance to PD-L1 blockade by suppressing IFN-γ signaling;Acta Pharmacologica Sinica;2024-09-02

3. Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma;Biomedicine & Pharmacotherapy;2024-08

4. NEK2 promotes the migration, invasion, proliferation of ESCC and mediates ESCC immunotherapy;Heliyon;2024-05

5. NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells;Neoplasma;2024